4,668 Shares in Medpace Holdings, Inc. $MEDP Purchased by Monument Capital Management

Key Points

• Monument Capital Management purchased 4,668 Medpace shares worth approximately $2.9 million, while institutional investors collectively own 77.98% of the company.
• Medpace’s CEO sold 21,966 shares for about $13.7 million; insiders have sold roughly $208 million in stock over the past quarter.
• Medpace exceeded quarterly earnings and revenue expectations, reporting $4.25 EPS and $707.33 million in revenue. Analysts maintain a consensus “Hold” rating with a $607.73 price target.

Monument Capital Management purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,668 shares of the company's stock, valued at approximately $2,914,000.

Several other hedge funds have also recently bought and sold shares of MEDP. BlackRock Inc. purchased a new stake in Medpace during the second quarter worth $1,323,047,000. State Street Corp raised its stake in shares of Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company's stock worth $376,483,000 after buying an additional 28,666 shares during the last quarter. Wasatch Advisors LP raised its stake in shares of Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company's stock worth $371,634,000 after buying an additional 125,625 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after buying an additional 38,760 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Medpace by 19.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company's stock worth $210,637,000 after buying an additional 60,883 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Medpace

In other Medpace news, CEO August Troendle sold 21,966 shares of Medpace stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the sale, the chief executive officer directly owned 338,225 shares of the company's stock, valued at approximately $211,549,590.75. The trade was a 6.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 336,140 shares of company stock worth $208,008,328 in the last quarter. 20.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

MEDP has been the subject of several recent research reports. Leerink Partners set a $620.00 target price on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets upped their price target on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a report on Friday, July 24th. Royal Bank Of Canada raised their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Finally, Barclays upped their target price on Medpace from $600.00 to $625.00 and gave the company an "equal weight" rating in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus price target of $607.73.

Medpace Trading Down 0.3%

NASDAQ:MEDP opened at $602.70 on Friday. The firm has a market cap of $16.82 billion, a price-to-earnings ratio of 35.33, a price-to-earnings-growth ratio of 2.70 and a beta of 1.18. The company's 50-day moving average is $602.08 and its two-hundred day moving average is $525.93. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.